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Background: The use of recombinant viral vectors expressing T. gondii antigens is a safe and efficient approach
to induce immune responses against the parasite, as well as a valuable tool for vaccine development. We have
previously prolonged the survival time of mice challenged with the RH strain of T. gondii by immunizing the mice
with a eukaryotic vector expressing the protein ROP18 of T. gondii. We are now looking for ways to improve this
vaccination strategy and enhance protection.
Methods: In this study, we constructed and characterized a novel recombinant canine adenovirus type 2 expressing
ROP18 (CAV-2-ROP18) of T. gondii by cytopathic effect (CPE) and indirect immunofluorescence assay (IFA) following
transfection into MDCK cells. Intramuscular immunization of Kunming mice with CAV-2-ROP18 was carried out to
evaluate humoral and cellular immune responses.
Results: The vaccination of experimental mice with CAV-2-ROP18 elicited antibody production against ROP18, including
high levels of a mixed IgG1/IgG2a and significant production of IFN-γ or IL-2, and displayed a significant bias towards a
helper T cell type 1 (Th1) profile. Furthermore, the presence of T. gondii-specific IFN-γ-production and TNF-α-production
T cells was elicited in both CD4+ and CD8+ T cell compartments. Significantly higher survival rates (40%) occurred in the
experimental group, and a reduction in brain cyst burden was detected in vaccinated mice.
Conclusion: These results demonstrate the potential use of a CAV vector harboring the ROP18 gene in the
development of a vaccine against acute and chronic toxoplasmosis.
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Toxoplasma gondii is an obligate, intracellular parasite
which belongs to the phylum Apicomplexa [1]. The
parasite can infect all warm-blooded mammals. In
humans it is one of the major opportunistic parasites that
infects immunocompromised individuals and pregnant
women [2-4], causing congenital defects in newborns and* Correspondence: ziguoyuan@scau.edu.cn
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unless otherwise stated.severe, disseminated disease in adults. Toxoplasmosis also
causes considerable economic losses in livestock, espe-
cially in pigs and sheep [5]. Chemical treatments for acute
and chronic toxoplasmosis are currently available, but
they are not acceptable due to parasite drug-resistant and
chemical residues in food [6,7]. Because of the public
health and eco2nomic consequences of T. gondii infection
in humans and animals, the development of a vaccine is
needed for disease prevention.
The T. gondii ROP18 protein is a polymorphic serine-
threonine kinase which is secreted in the host cell during
the invasion process, and its catalytic activity is required
for the acute virulence phenotype. ROP18 is consideredis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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T. gondii infection [8,9]. Previous research has demon-
strated that an additional ligand-binding pocket outside of
the active site cleft is a key element of the ROP18 Ser/Thr
protein kinase for mediating acute virulence in mice [10].
The use of recombinant viral vectors has great poten-
tial for the development of more immunogenic vaccines
against protozoan parasites. Viral vectors typically elicit
efficient expression of the foreign antigens they encode,
which facilitate the presentation and development of
specific immune responses against the recombinant anti-
gen [11,12]. Here we describe the development of a
recombinant canine adenovirus expressing the ROP18
gene of T. gondii that partially protected mice against
challenge with the RH strain (genotype I) and Prugniaud
(PRU) strain (genotype II) of T. gondii.
Methods
Mice, cell and parasites
One hundred and thirty-two specific-pathogen-free (SPF)
grade, female, inbred Kunming mice, 6 to 8 weeks old,
were purchased from the Sun Yat-Sen University Labora-
tory Animal Center. All mice were handled properly
according to the Animal Ethics Procedures and Guidelines
of the People’s Republic of China. The study was approved
by the Animal Ethics Committee of South China Agricul-
tural University (permit SCAUAEM-2013-39). All mice
were maintained under standard conventional conditions,
with food and water ad libitum.
Madin-Darby canine kidney cell lines (MDCK) were
cultivated and two T. gondii strains (RH and PRU) were
used in our lab (see Additional file 1).
The construction of pPolyII-CAV-ΔE3-ROP18
The construction of pPolyII-CAV-ΔE3-ROP18 (Figure 1)
was performed as described in Additional file 2.
Transfection of recombinant genome in MDCK cells and
identification of ROP18 expression from CAV-2-ROP18
Five micrograms of pPolyII-CAV-ΔE3-ROP18 were digested
with Asc I and Pme I to release the linear recombinant
genome. After extraction with chloroform and precipita-
tion with ethanol, the recombinant genome was used to
transfect MDCK cells at 70–80% confluency with Lipofec-
tamine 2000TM (Invitrogen). The transfected MDCK cells
were passaged routinely until a typical CAV-2 cytopathic
effect (CPE) was observed.
For identification of the expression of ROP18 by recom-
binant CAV-2-ROP18, the indirect immunofluorescence
assay (IFA) was done as reported in Additional file 3 [4].
Vaccination procedure and challenge
All mice were randomly assigned into one of four
experimental groups (33 mice per group). Group I wasintramuscularly inoculated once with 0.1 ml CAV-2-
ROP18 (10 8.125 p.f.u. ml−1); group II received 0.1 ml
CAV-2 (108.25 p.f.u. ml−1) intramuscularly once as a
negative control; group III was inoculated intramuscu-
larly with 0.1 ml PBS as control at weeks 0, 2 and 4; and
group IV was not injected with anything as a negative
control. Blood was collected from the lateral saphenous
vein of a hind limb of 5 mice per group one day prior to
each immunization and at intervals of two weeks after
inoculation.Sera were separated and stored at -20°C until
analyzed for specific antibodies. Pre-immune sera were
used as negative controls.
Eight weeks after the immunization, 20 mice in each
group were challenged intraperitoneally (i.p.) with 1 × 103
tachyzoites of the virulent T. gondii RH strain, and 10
other mice were inoculated intragastrically with 5 cysts of
the PRU strain. All mice were observed daily for mortality.
Two months after the challenge, the surviving mice were
euthanized and their brains were removed. Each brain was
homogenized in 2 ml of PBS. The mean number of cysts
per brain was determined by counting in three samples of
25 μl aliquots of each homogenized brain under an optical
microscope.Humoral response
Levels of antigen-specific IgG, IgG1 and IgG2a immuno-
globulins in serum samples were examined as previously
described (see Additional file 4) [13].
CAV-2 hemagglutination inhibition (HI) antibody titers
were determined by a micro method with a slight modifi-
cation (see Additional file 5) [14].Lymphocyte proliferation assay
At week 8 (post-immunization), splenocytes were harvested
from each of the three immunized mice from each group,
separately. Next, the spleen cells proliferative response was
measured as mentioned above (for details, see Additional
file 6) [4,15,16].Cytokine assays
Detection of cytokines was carried out according to the
method previously described (see Additional file 7 for
details) [4].Evaluation of CTL activity
Peripheral blood mononuclear cells (PBMCs) of mice
were segregated from 3 mice per group and single-cell
suspensions were prepared from mice 8-weeks after the
immunization, and the activity of cytotoxic T lymphocytes
(CTL) was measured by CytoTox 96® Non-Radioactive
Cytotoxicity Assay Kits (Promega, USA) as previously
reported (see Additional file 8) [15].
Figure 1 Schematic representation of the construction of recombinant plasmid pPolyII-CAV-△E3-ROP18 by in vitro ligation. E3, the E3
region of CAV-2; CMV, human cytomegalovirus (hCMV) immediate-early gene promoter; polyA, the SV40 early mRNA polyadenylation signal. Bold
letters were those enzymes used in plasmid construction.
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Co-expression of CD3+ with CD4+ and CD8+ on lympho-
cytes of splenocytes were determined by flow cytometry as
previously mentioned (see Additional file 9) [13].
Detection of intracellular cytokines was carried out
according to the method of Additional file 9.
Statistical analysis
All data were processed and analyzed by SPSS13.0 Data
Editor (SPSS Inc., Chicago, IL, USA). Mean antibody
responses, lymphoproliferation, cytokine production and
CTL were compared between groups by using one-way
ANOVA. If data are not normally distributed, the non-
parametric Kruskal-Wallis test was used in the study.
Values of P < 0.05 were considered significant.
Results
Recovery and identification of CAV-2-ROP18
Seven days after transfection of the recombinant genome
pPolyII-CAV-ΔE3-ROP18 into MDCK cells, typical
adenovirus-like CPE (grape-cluster-like cells) was ob-
served under an optical microscope (200×, Figure 2). The
growth characteristics of the recombinant virus was simi-
lar to that of the canine adenovirus vaccine strain YCA18
(data not shown). The identification of the recombinant
virus genome by restriction endonuclease digestion and
PCR amplification confirmed that the ROP18 gene and its
expression cassette were included in the recombinant
virus (data not shown). IFA demonstrates expression of
ROP18 following transduction of MDCK cells with
CAV2-ROP18, whereas no fluorescence was observed in
negative control MDCK cells by use of an anti-ROP18
polyclonal antiserum (Figure 3).
Evaluation of humoral responses
Using ELISA, antibody titers significantly increased in
the recombinant virus CVA-2-ROP18 group at week 2, 4
and 6 after immunization, compared to CAV-2, PBS and
blank control immunized group (P < 0.05) (Figure 4A).
Subclasses of immunoglobulins specific to T. gondii were
analyzed in the sera (as shown in Figure 4B). Both IgG1Figure 2 Cytopathic effects on MDCK cells after transfection (×400). Nand IgG2a were tested in sera of mice immunized with
CAV-2-ROP18, and the ratios of IgG1 to IgG2a in the
groups I - IV were 2.69, 1.02, 1.08, and 1.09, respectively.
There was no significant difference in IgG1 and IgG2a
levels between the groups immunized CAV-2, PBS, and
nothing (P > 0.05). It is known that production of IgG
subclasses is driven by cytokines secreted during cellular
immune responses. Therefore, the presence of IgG1 and
IgG2a indirectly suggests that the vaccination protocol
also promoted activation of a cell-mediated response.
HI antibodies against CAV-2 were detected in all mice
vaccinated with CAV-2 and the recombinant CAV-2-
ROP18 at 2 weeks post-primary immunization, reaching
comparable titers throughout the test period. In addition,
HI titers were up to 1:128 eight weeks after primary
vaccination (Table 1). In mice vaccinated with PBS and
those not vaccinated, specific antibodies to CAV-2 were
not detected.
Cellular immune response analysis
Splenocytes from mice immunized with CAV-2-ROP18
showed a very significant proliferative response to ROP18
(P < 0.05), and splenocyte proliferation was ∼ 21-fold
higher than proliferation by splenocytes from groups im-
munized with CAV-2, PBS and negative control (P < 0.05).
Meanwhile, splenocytes from all groups proliferated to
comparable levels in response to the mitogen ConA
(Table 2). Significant CTL activity was tested in mice
immunized with CAV-2-ROP18 (at E:T value of 100:1;
Figure 5).
For further characterization of cellular immune re-
sponses, the CD3+/CD4+ T cells and CD3+/CD8+ T cells
were shown in Figure 6.The percentage of CD3+/CD4+ T
cells and CD3+/CD8+ T cells were significantly increased
in mice immunized with CAV-2-ROP18 compared to
those with CAV-2, PBS, or blank control groups. Similarly,
recombinant virus immunization CAV-2-ROP18 signifi-
cantly altered CD4+ or CD8+ T cell profiles in terms of
IFN-γ (Figure 7) and TNF-α (Figure 8) expression in com-
parison with all controls. There was no significant differ-
ence between the three control groups (P > 0.05).ormal cells (A); transfected and cytopathic cells (B).
Figure 3 Expression analyses of ROP18 protein in transfected MDCK cells by IFA at 48 h post-transfection with a presumptive recombinant
virus CAV-2-ROP18: (A) Non-transfected MDCK cells; (B) MDCK cells detected with T. gondii-positive serum post-transfection with a
presumptive recombinant virus CAV-2-ROP18. The pictures were showed under 400× microscope.
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The cell-mediated immunity induced in the immunized
mice was further evaluated by measuring the amount of
cytokines IL-2, IL-4, IL-10 and IFN-γ. As shown in Table 2,
values of IL-2 and IFN-γ in CAV-2-ROP18 immunization
group are 431.07 ± 28.94 pg/ml and 914.26 ± 36.56 pg/ml,
which are very significantly higher than in the control
groups (CAV 47.23 ± 7.59 pg/ml and 44.28 ± 9.37 pg/ml;
PBS 52.60 ± 11.97 pg/ml and 46.13 ± 10.27 pg/ml; blank
control 51.45 ± 3.88 pg/ml and 42.98 ± 6.76 pg/ml) (P <
0.05). For IL-4, low levels of IL-4 showed a slight but
significantly production from the splenocytes from mice
immunized with CAV-2-ROP18, compared to three con-
trol groups (P < 0.05), further confirming the results of the
IgG subclass. On the other hand, no statistically signifi-
cant differences could be found in the amount of IL-10
between the immunized and control groups (P > 0.05).
Protection of mice against challenge with T. gondii
To examine protective immunity, 20 mice of each group
were given an intraperitoneal injection of 1 × 103Figure 4 Detection of CAV-2-ROP18 immunization on the antibody resp
immunization. (A) Determination of specific anti-ROP18 IgG antibodies in the
subclass profile in the sera of the immunized Kunming mice. Results are expre
statistically significant difference (P < 0.05) are indicated by an asterisk (*).tachyzoites of T. gondii RH strain at 8 weeks after vac-
cination. Mortality was checked daily. The percentages
of survival in the different groups of mice are shown in
Figure 9. Those mice immunized with only a single dose
of CAV-2-ROP18 showed 40% protection until 60 days
after challenge. The administration of either CAV-2 or
PBS did not prevent mortality (mice died within 7 days).
Also, we evaluated the immunoprotective effect by
counting the number of cysts in a chronic model chal-
lenge with 5 cysts of strain PRU administration by gav-
age. As shown in Table 3, we observed that mice from
the CAV-2-ROP18 vaccination group developed a sig-
nificantly lower (P < 0.05) number of brain cysts (8000 ±
1414 cysts per brain) in comparison to mice from the
other three control control groups (approximately 18000
cysts).
Discussion
In this study, a recombinant CAV-2 genome carrying
the ROP18 expression cassette was first constructed, and
the recombinant adenovirus was then generated byonse. Serum samples were collected at weeks 0, 2, 4 and 6 post-primary
sera of Kunming mice. (B) Determination of the specific anti-ROP18 IgG
ssed as means of the OD490 value and standard deviation (n = 5), and
Table 1 CAV-2 HI antibody titers in mice immunized with PBS, CAV-2 and CAV-2-ROP18
Group (n = 3) 0 week 2 weeks 4 weeks 6 weeks 8 weeks 10 weeks
CAV-2-ROP18 <1:2 1:8-1:16 1:16-1:32 1:64 1:128 1:64-1:128
CAV-2 <1:2 1:8-1:16 1:16-1:32 1:64 1:128 1:64-1:128
PBS <1:2 <1:2 <1:2 <1:2 <1:2 <1:2
Blank Control <1:2 <1:2 <1:2 <1:2 <1:2 <1:2
Li et al. BMC Infectious Diseases  (2015) 15:114 Page 6 of 10transfecting MDCK cells with the recombinant genome.
Regarding the vaccine vectors used for ROP18 expression
of T. gondii, we started our work with the replication-
competent CAV. Besides being highly efficient for trans-
gene expression “in vivo” and being safe for administration,
adenoviral vectors also have intrinsic adjuvant properties
capable of activating an innate immune response via
TLR [17,18] and NLR [19] receptors. Meanwhile, several
different species of adenovirus have been developed by
homologous recombination with insertion of foreign genes
into the non-essential E3 region [20,21]. Replication-
defective adenoviruses have often been utilized as
candidate vaccine vectors. However, clinical application
of the best-studied human adenovirus type-5 (AdHu5)
is limited by the high prevalence of preexisting immunity
resulting from natural infection [22,23]. Many researchers
are apprehensive about the problem of a long-acting
vaccine in the animal body, because the antibodies could
be produced when the animals were infected by CAV in
nature. In this study we used the CAV-2 as a vector to
express the ROP18 antigen, because CAV-2 is an artificial
domestic strain [24], and previous exposure to CAV-2 is
low [25]. In the study, titers of HI antibodies to CAV-2
induced by the recombinant virus CAV-2-ROP18 were
similar to those induced by CAV-2 vaccine strain, which
indicates that the recombinant virus retains its ability to
stimulate an effective immune response against CAV.
We also evaluated the Th1 and/or Th2 immune response
in mice immunized by prime-boost strategy. The IFN-γ
secreted by Th1 cells favors the IgG2a switch, while IL-4
produced by Th2 cells regulates the IgG1 switch [26]. The
development of potent Th1-type immune response is
essential for the control of T. gondii infection [27,28].Table 2 Cytokine production by splenocytes of immunized m
immunization*
Group (n = 3) Cytokine production (pg/mL)
IFN-γ IL-2 IL-4
CAV-2-ROP18 (I) 914.26 ± 36.56a 431.07 ± 28.94a 197.29 ± 2
CAV-2 (II) 44.28 ± 9.37b 47.23 ± 7.59b 52.65 ± 9.
PBS (III) 46.13 ± 10.27b 52.60 ± 11.97b 54.87 ± 9.
Blank Control (IV) 42.98 ± 6.76b 51.45 ± 3.88b 53.38 ± 5.
*Data are reported as mean ± SD.
#Splenocytes from mice were collected 8-weeks after the immunization.
Values for IL-10 and IFN-γ are for 72 h, values for IL-2 and IL-4 are for 24 h.
Within each column, groups with different superscripts are different (P < 0.05).As the indicator for activated Th1 lymphocytes, the
pro-inflammatory cytokines including IFN-γ and IL-2
are also involved in the protection against the infection
[29,30]. Our results showed that in contrast with the
controls, immunization with CAV-2-ROP18 induced
the production of high levels of IL-2 and IFN-γ (as well
as IgG2a), which are associated with Th1-type mediated
immunity. Nevertheless, Th2-type cytokines, both IL-4 and
IL-10, may partially inhibit the secretion of pro-
inflammatory cytokines and prevent CD4+ T cell-mediated
severe immunopathology during the acute and chronic
stage of T. gondii invasion [31]. The production of IL-4 in
early infection inhibits protective Th1 cell differentiation
most likely by either direct or indirect inhibition of IFN-γ
production [32]. A slight increase in the release of IL-4 (as
well as IgG1) in combination with the high levels of IL-2
and IFN-γ suggested the activation of an appropriate T
helper response, primarily a specific Th1-biased cellular
immune response after immunization with CAV-2-ROP18.
There was no difference in IL-10 production between vac-
cinated and control groups. The results suggested that
Th1-mediated cellular immunity in the group immunized
with CAV-2-ROP18 is not dependent on IL-10 production
during the cellular response against toxoplasmosis.
In addition to cellular immunity, humoral immunity
resulting in the production of antigen-specific IgG anti-
bodies also seems to be important in controlling T.
gondii invasion [33]. It has been reported that T. gondii
infection could lead to B cell responses resulting in pro-
duction of antibodies, which limit the spread of parasites
by inhibiting the attachment of tachyzoites to host cell
receptors and thus promoting intracellular killing of
antibody-coated parasites by macrophages [33]. Our studyice after stimulation by ROP18 protein at 8-weeks post
Proliferation (Stimulation Index)#
IL-10 ROP18 ConA
9.98a 44.37 ± 38.54a 4.87 ± 0.65a 2.93 ± 0.43a
24b 38.49 ± 5.48a 0.23 ± 0.06b 3.07 ± 0.19a
45b 41.36 ± 5.23a 0.26 ± 0.10b 2.81 ± 0.32a
97b 40.63 ± 6.74a 0.27 ± 0.07b 2.84 ± 0.26a
Figure 5 CTL activity of splenocytes from vaccinated mice 8
weeks after the first immunization. These splenocytes were tested
for ROP18-specific CTL activity of ROP18 target cells loaded with
CAV-2-ROP18 (triangle), CAV-2 (circle), PBS (crossing) or nothing
(diamond). Data shown represent one experiment of three
performed with similar results. E/T ratios are indicated on the
horizontal axis. The vertical axis shows T.gondii-specific lysis as a
percentage of the total possible lysis (% specific lysis).
Figure 7 The expression of IFN-γ on CD4+ and CD8+ T cells using
flow cytometry analysis. The percentages of IFN-γ-producting cells
inside CD4+ T cell gate (A) and IFN-γ-producting cells inside CD8+ T cell
gate (B) in mice spleen cells. Data are reported as mean ± SD.
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nificantly increased the antigen-specific IgG compared
with the mice immunized with CAV-2 or PBS. This result
indicated that adenovirus vector is highly efficient for gene
transfer and expression.Figure 6 Analysis of lymphocyte subpopulations (CD3+/CD4+
of CD3+/CD8+) responses in Kunming mice vaccinated with
CAV-2-ROP18 or nothing. (A) The percentages of CD3+/CD4+ T
lymphocytes. (B) The percentages of CD3+/CD8+ T lymphocytes.
Data are reported as mean ± SD.Previous studies demonstrated that DNA vaccine ex-
pressing T. gondii antigens could elicit both humoral
and cell-mediated immunity and prolong the survival
time in mice [4,13,15,34-37]. However, no protection was
observed in mice, regardless of DNA vaccine or recombin-
ant virus vaccine [4,13,15,34-37]. In our study, we im-
proved the survival rate, which is up to 40% protection in
mice immunized with CAV-2-ROP18 after challenge with
lethal RH strain of T. gondii. PRU strain (genotype II) of T.
gondii was used in our research in order to scientifically
evaluate immunoprotection while using many more mice
in this test. We also obtained a 57.3% reduction in brain
cysts after immunization of mice with CAV-2-ROP18.
Furthermore, the cross-protective immunity has been
demonstrated, despite the existing 7.5% sequence vari-
ation between type I (RH strain) and type II (PRU strain).
CAV-2-ROP18 could elicit antigen-specific CD4+ T
cells and CD8+ T cells responses in mice. However, their
major advantage at the immunological level has been
their capacity to induce antigen-specific CD8+ T cell
responses, including CTLs, which is a major mechanism
of protection against intracellular pathogens. Some stud-
ies have shown that CTLs are involved in cyst control
during T. gondii infection in a mechanism mediated by
perforin [38]. Meanwhile, it is very important that CD8+ T
cells, particularly in synergy with CD4+ T cells, contrib-
uted to the control of the spreading and development of
T. gondii infection [39,40]. In agreement with this efficacy,
we observed the increase of the percentage of T CD8+ and
T CD4+ cells in mice immunized with CAV-2-ROP18,
which also suggested the activation of CD4+ and CD8+ T
Figure 8 The expression of TNF-α on CD4+ and CD8+ T cells using flow cytometry analysis. A, percentages of TNF-α-producting cells inside
CD4+ T cell gate. B, percentages of TNF-α-producting cells inside CD8+ T cell gate. Data are reported as mean ± SD.
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toxic activity against T. gondii. Additionally, the present
study showed that CD4+ and CD8+ T cells were up-
regulated after the administration of CAV-2-ROP18, at
least in terms of frequency of both type cells producing
IFN-γ of TNF-α, which was observed in cytotoxicity assayFigure 9 Survival rate of mice immunized with CAV-2-ROP18 (◊),
CAV-2 (Δ), PBS (☼) and nothing (*), then challenged with 1 × 103
tachyzoites. Each group had 20 mice. Statistically significant differences
(P< 0.05) are indicated by an asterisk (*), which of CAV-2-ROP18 are listed
differently compared to the other other control groups.in vitro. The CTL activity in the group immunized with
CAV-2-ROP18 was significantly higher than that of the
group injected with pVAX-ROP18 alone, as previously
described (T. gondii-specific lysis is 68% vs 47%) [13].Conclusions
In summary, our work presents the successful use of re-
combinant virus CAV-2-ROP18 in vaccination protocols
to protect against intraperitoneal and intragastrical chal-
lenge with virulent RH strain or attenuated PRU strain of
T. gondii. This system was shown to be extremely efficient
in eliciting humoral and cellular immune responses.
Therefore, the CAV-2-ROP18 may be potentially useful in
the development of an effective vaccine against T. gondii
infection in the future.Table 3 Mean cyst burden per mouse brain 30 days after
injection with5 cysts of PRU strain by intragastrical route
Group (n = 5) No. of brain cysts* Reduction (%)#
CAV-2-ROP18 (I) 8000 ± 1414a 57.3
CAV-2 (II) 17480 ± 1584b 6.6
PBS (III) 18080 ± 642b 3.4
Blank Control (IV) 18720 ± 955b -
*Data are reported as mean ± SD.
a,bThe same letter indicates no difference (P > 0.05), whereas different letters
indicate a significant difference (P < 0.05).
#From the values for the blank control.
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